Skip to content
TrialScanner

NCT05276830

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Phase 2TerminatedBTAIQLead

Registry record

Lead sponsor
BioXcel Therapeutics Inc
Conditions
Agitation; Dementia
Primary completion
Apr 1, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05276830 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.